Does Rallies show 13F holders for BIOA?

Yes. Rallies tracks hedge fund and 13F ownership data for BIOA, including fund names, share counts, latest tracked quarter, and position changes when available.

Is BIOA research on Rallies investment advice?

No. Rallies provides research, data, and educational context for BIOA. It does not provide personalized investment advice.

BIOA (BioAge Labs, Inc. Common Stock) Stock Analysis - Hedge Fund Holdings

BioAge Labs, Inc. Common Stock (BIOA) is a publicly traded Healthcare sector company. As of May 20, 2026, BIOA trades at $16.26 with a market cap of $681.90M and a P/E ratio of -6.84. BIOA moved -0.61% today. Year to date, BIOA is +27.59%; over the trailing twelve months it is +315.48%. Its 52-week range spans $2.88 to $26.62. Analyst consensus is buy with an average price target of $47.83. Rallies surfaces BIOA's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who owns BIOA stock?

Hedge funds tracked by Rallies that own BIOA include Orbimed Advisors and Soros Fund. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for BioAge Labs, Inc. Common Stock.

BIOA Key Metrics

Key financial metrics for BIOA
Metric	Value
Price	$16.26
Market Cap	$681.90M
P/E Ratio	-6.84
EPS	$-2.40
Dividend Yield	0.00%
52-Week High	$26.62
52-Week Low	$2.88
Volume	147.40K
Avg Volume	0
Revenue (TTM)	$10.32M
Net Income	$-89.93M
Gross Margin	0.00%

Top Hedge Funds Holding BIOA

Orbimed Advisors holds 711.81K shares of BIOA, changed -10.00% as of Mar 31, 2026.
Soros Fund holds 100.00K shares of BIOA, changed +0.00% as of Sep 30, 2024.

Latest BIOA News

Cell Therapy Market to Top $20 Billion by 2030 as BioAge Labs Advances Anti-Aging Research — May 20, 2026
BioAge Achieves 86% hsCRP Reduction in Phase 1, Secures $132.3M — May 8, 2026
BioAge to Unveil BGE-102 Phase 1 NLRP3 Inhibitor Data on May 8 — May 4, 2026
BioAge’s BGE-102 Delivers 85–87% hsCRP Cuts, Launching Mid-2026 Phase 2 Trial — Apr 21, 2026
BioAge Labs Raises $132.3M and Reports 86% BGE-102 Phase 1 hsCRP Reduction — Mar 24, 2026

Recent BIOA Insider Trades

RUBIN PAUL D sold 8.82K (~$157.08K) on Apr 1, 2026.
RUBIN PAUL D sold 7.43K (~$150.89K) on Mar 2, 2026.
RUBIN PAUL D sold 7.43K (~$139.37K) on Feb 2, 2026.

BIOA Analyst Consensus

7 analysts cover BIOA: 0 strong buy, 5 buy, 2 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $47.83.

Common questions about BIOA

Who owns BIOA stock?: Hedge funds tracked by Rallies that own BIOA include Orbimed Advisors and Soros Fund. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for BioAge Labs, Inc. Common Stock.
Does Rallies show 13F holders for BIOA?: Yes. Rallies tracks hedge fund and 13F ownership data for BIOA, including fund names, share counts, latest tracked quarter, and position changes when available.
Is BIOA research on Rallies investment advice?: No. Rallies provides research, data, and educational context for BIOA. It does not provide personalized investment advice.